Decrement of compound muscle action potential is related to mutation type in myotonia congenita.
Decrement of the compound muscle action potential (CMAP) during 10-HZ repetitive nerve stimulation is thought to be an unusual finding in dominant myotonia congenita, and has not previously been reported in patients with the genetically verified disorder. It was the purpose of the present study to elucidate the relation between decrement and CLCN1 mutation type in myotonia congenita. Decrement and genotypes were studied in eight Danish families with myotonia congenita. Six patients with the known dominant mutation P480L had decrements of 30-84%. Patients heterozygous for the R894X mutation had decrements of 20-47%. Three novel CLCN1 mutations (two dominant and one recessive) were found segregating with the Thomsen/Becker phenotypes. In families with the novel dominant mutations M128V and E193K, decrement was absent in all family members tested. In conclusion, CMAP decrement may be pronounced in dominant myotonia congenita, and the presence of decrement is related to mutation type.
Colding-Jørgensen
Eskild
E
Department of Clinical Neurophysiology, National University Hospital, Rigshospitalet, Copenhagen, Denmark.
DunØ
Morten
M
Schwartz
Marianne
M
Vissing
John
J
D000200:Action Potentials / Q000235:genetics* / Q000502:physiology*; D000328:Adult; D000367:Age Factors; D000368:Aged; D018118:Chloride Channels / Q000235:genetics; D004252:DNA Mutational Analysis; D003718:Denmark; D004558:Electric Stimulation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000235:genetics / Q000502:physiology; D018908:Muscle Weakness / Q000235:genetics / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000503:physiopathology*; D009154:Mutation / Q000235:genetics* / Q000502:physiology*; D009224:Myotonia Congenita / Q000235:genetics* / Q000503:physiopathology*; D010375:Pedigree; D012737:Sex Factors
C086321:CLC-1 channel; D018118:Chloride Channels